These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 20817384)

  • 21. Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies.
    Pirastu R; Fais R; Messina M; Bini V; Spiga S; Falconieri D; Diana M
    Drug Alcohol Depend; 2006 Jun; 83(2):163-8. PubMed ID: 16343811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
    Fingerhood MI; King VL; Brooner RK; Rastegar DA
    Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Buprenorphine and methadone to opiate addicts--a randomized trial].
    Kristensen Ø; Espegren O; Asland R; Jakobsen E; Lie Ø; Seiler S
    Tidsskr Nor Laegeforen; 2005 Jan; 125(2):148-51. PubMed ID: 15665884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.
    Bell J; Trinh L; Butler B; Randall D; Rubin G
    Addiction; 2009 Jul; 104(7):1193-200. PubMed ID: 19563562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma.
    Holbrook AM
    Am J Drug Alcohol Abuse; 2015; 41(5):371-3. PubMed ID: 26154531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.
    Marsch LA; Stephens MA; Mudric T; Strain EC; Bigelow GE; Johnson RE
    Exp Clin Psychopharmacol; 2005 Nov; 13(4):293-302. PubMed ID: 16366759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
    Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients.
    Soyka M; Apelt SM; Lieb M; Wittchen HU
    J Clin Psychopharmacol; 2006 Dec; 26(6):657-60. PubMed ID: 17110826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimising the benefits of unobserved dose administration for stable opioid maintenance patients: follow-up of a randomised trial.
    Bell JR; Ryan A; Mutch C; Batey R; Rea F
    Drug Alcohol Depend; 2008 Jul; 96(1-2):183-6. PubMed ID: 18423901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid dependence - management in general practice.
    Frei M
    Aust Fam Physician; 2010 Aug; 39(8):548-52. PubMed ID: 20877747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
    Turner BJ; Laine C; Lin YT; Lynch K
    Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of buprenorphine and methadone effects on opiate self-administration in primates.
    Mello NK; Bree MP; Mendelson JH
    J Pharmacol Exp Ther; 1983 May; 225(2):378-86. PubMed ID: 6188822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of patients with moderately severe methadone dependence onto buprenorphine.
    Glasper A; Reed LJ; de Wet CJ; Gossop M; Bearn J
    Addict Biol; 2005 Jun; 10(2):149-55. PubMed ID: 16191667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial.
    Wedam EF; Bigelow GE; Johnson RE; Nuzzo PA; Haigney MC
    Arch Intern Med; 2007 Dec; 167(22):2469-75. PubMed ID: 18071169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine and methadone: a comparison of patient completion rates during inpatient detoxification.
    Blondell RD; Smith SJ; Servoss TJ; DeVaul SK; Simons RL
    J Addict Dis; 2007; 26(2):3-11. PubMed ID: 17594993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: A randomized controlled trial.
    Robertson JR; Raab GM; Bruce M; McKenzie JS; Storkey HR; Salter A
    Addiction; 2006 Dec; 101(12):1752-9. PubMed ID: 17156174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome evaluation of the opioid agonist maintenance treatment in Iran.
    Esmaeili HR; Ziaddinni H; Nikravesh MR; Baneshi MR; Nakhaee N
    Drug Alcohol Rev; 2014 Mar; 33(2):186-93. PubMed ID: 24428135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention.
    Burns L; Randall D; Hall WD; Law M; Butler T; Bell J; Degenhardt L
    Addiction; 2009 Aug; 104(8):1363-72. PubMed ID: 19549053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system.
    Gryczynski J; Jaffe JH; Schwartz RP; Dušek KA; Gugsa N; Monroe CL; O'Grady KE; Olsen YK; Mitchell SG
    Am J Addict; 2013; 22(3):285-91. PubMed ID: 23617873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.